Neurocrine Biosciences, Inc. provided earnings guidance for the full year of 2024. For the year, company expects Net Product Sales of $2,100 million to $2,200 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
134.6 USD | +0.05% | -0.44% | +2.22% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.22% | 13.54B | |
+16.84% | 121B | |
+20.95% | 114B | |
+18.05% | 23.61B | |
-18.20% | 20.43B | |
-16.24% | 16.55B | |
-11.36% | 16.45B | |
-44.45% | 15.59B | |
+69.80% | 15.19B | |
+124.96% | 10.96B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024